Women’s Health Update | Summer 2026

Key takeaways from the update:

• Consumer preferences are shifting toward condition-specific, science-backed women’s health solutions, particularly across intimate health, fertility, menopause, hormonal wellness, and nutrition.
• Women’s intimate health remains a significant consumer healthcare category, with the U.S. feminine treatment market exceeding $700mn and the itch & yeast segment representing 46% of feminine treatment sales.
• FemiClear operates in the approximately $321mn U.S. itch & yeast treatment segment, the largest subcategory within feminine treatments, and has delivered double-digit sales growth while many larger competitors have declined.
• Differentiated women’s health brands continue to attract strategic interest, particularly those combining targeted product positioning, natural formulations, clinical credibility, and strong consumer engagement.
• The update highlights selected innovators across the category, including companies focused on fertility and hormone monitoring, vaginal microbiome health, maternal nutrition, menopause, reproductive care, and broader women’s wellness.